Analysts forecast that Redhill Biopharma Ltd. (NASDAQ:RDHL) will report earnings of ($0.58) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Redhill Biopharma’s earnings, with estimates ranging from ($0.62) to ($0.51). Redhill Biopharma reported earnings of ($0.60) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 3.3%. The company is expected to announce its next earnings results on Tuesday, July 25th.
According to Zacks, analysts expect that Redhill Biopharma will report full year earnings of ($2.23) per share for the current financial year, with EPS estimates ranging from ($2.35) to ($2.04). For the next fiscal year, analysts expect that the business will post earnings of ($2.23) per share, with EPS estimates ranging from ($2.40) to ($2.05). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Redhill Biopharma.
Redhill Biopharma (NASDAQ:RDHL) last released its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.50) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.64) by $0.14.
A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Redhill Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. FBR & Co restated a “buy” rating on shares of Redhill Biopharma in a research note on Friday, June 16th. HC Wainwright set a $33.00 price target on shares of Redhill Biopharma and gave the company a “buy” rating in a research note on Thursday, June 15th. Finally, Roth Capital set a $26.00 price target on shares of Redhill Biopharma and gave the company a “buy” rating in a research note on Thursday, May 4th.
A number of large investors have recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Redhill Biopharma during the fourth quarter valued at approximately $4,087,000. Renaissance Technologies LLC increased its stake in Redhill Biopharma by 144.1% in the first quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 36,600 shares in the last quarter. Jane Street Group LLC acquired a new stake in Redhill Biopharma during the first quarter valued at approximately $276,000. Family Management Corp acquired a new stake in Redhill Biopharma during the first quarter valued at approximately $163,000. Finally, Bank of New York Mellon Corp acquired a new stake in Redhill Biopharma during the first quarter valued at approximately $101,000. Institutional investors and hedge funds own 12.31% of the company’s stock.
Redhill Biopharma (NASDAQ RDHL) traded up 3.28% during trading on Wednesday, reaching $8.81. 76,147 shares of the company’s stock were exchanged. The firm’s market cap is $149.83 million. The stock’s 50 day moving average price is $9.43 and its 200 day moving average price is $9.89. Redhill Biopharma has a 52-week low of $8.20 and a 52-week high of $16.54.
About Redhill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with our FREE daily email newsletter.